- Home
- TTE vs GILD Comparison
TTE vs GILD Comparison
Compare TTE & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTE
- GILD
- Stock Information
- Founded
- TTE 1924
- GILD 1987
- Country
- TTE France
- GILD United States
- Employees
- TTE N/A
- GILD N/A
- Industry
- TTE Oil & Gas Production
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TTE Energy
- GILD Health Care
- Exchange
- TTE Nasdaq
- GILD Nasdaq
- Market Cap
- TTE 127.3B
- GILD 113.0B
- IPO Year
- TTE 1991
- GILD 1992
- Fundamental
- Price
- TTE $59.49
- GILD $91.84
- Analyst Decision
- TTE Hold
- GILD Buy
- Analyst Count
- TTE 5
- GILD 26
- Target Price
- TTE $72.42
- GILD $98.17
- AVG Volume (30 Days)
- TTE 2.1M
- GILD 6.6M
- Earning Date
- TTE 02-05-2025
- GILD 02-11-2025
- Dividend Yield
- TTE 5.59%
- GILD 3.35%
- EPS Growth
- TTE N/A
- GILD N/A
- EPS
- TTE 7.09
- GILD 0.10
- Revenue
- TTE $203,260,000,000.00
- GILD $28,299,000,000.00
- Revenue This Year
- TTE N/A
- GILD $6.50
- Revenue Next Year
- TTE N/A
- GILD $0.36
- P/E Ratio
- TTE $7.90
- GILD $908.39
- Revenue Growth
- TTE N/A
- GILD 3.31
- 52 Week Low
- TTE $53.29
- GILD $62.07
- 52 Week High
- TTE $74.97
- GILD $98.90
- Technical
- Relative Strength Index (RSI)
- TTE 71.31
- GILD 51.58
- Support Level
- TTE $56.17
- GILD $90.82
- Resistance Level
- TTE $59.81
- GILD $93.07
- Average True Range (ATR)
- TTE 0.71
- GILD 1.54
- MACD
- TTE 0.63
- GILD -0.03
- Stochastic Oscillator
- TTE 94.42
- GILD 56.28
About TTE TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2023, it produced 1.6 million barrels of liquids and 5.0 billion cubic feet of natural gas per day. At end-2023, reserves stood at 10.6 billion barrels of oil equivalent, 56% of which are liquids. During 2023, it had LNG sales of 44.3 metric tons. The company owns interests in refineries with capacity of nearly 2.0 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. At year-end, its gross installed renewable power generation capacity was 22.4 gigawatts.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).